33 results
DEFA14A
VOR
Vor Biopharma Inc
2 May 24
Additional proxy soliciting materials
4:08pm
Exchange Act of 1934, as amended.
Dr. Namouni, 55, has served as President, Research and Development of Blueprint Medicines Corporation (“Blueprint
8-K
VOR
Vor Biopharma Inc
2 May 24
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
4:07pm
Committee of the Board (the “Nominating Committee”).
Dr. Namouni, 55, has served as President, Research and Development of Blueprint Medicines
8-K
EX-99.1
VOR
Vor Biopharma Inc
2 May 24
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
4:07pm
of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines … research and development complements and strengthens the diverse perspectives on Vor’s Board and I look forward to working closely with him.”
Dr. Namouni
424B5
eaepfqy0
23 Dec 22
Prospectus supplement for primary offering
4:05pm
424B5
mb9nw py2
8 Dec 22
Prospectus supplement for primary offering
5:15pm
S-3
bk5do0lo8651ptp
14 Mar 22
Shelf registration
5:15pm
8-K
xtxbzy9qpj0di24hg
17 Jun 21
Entry into a Material Definitive Agreement
8:13am
8-K
EX-99.1
lu0aqgy c70kmk
17 Jun 21
Entry into a Material Definitive Agreement
8:13am